# Safety and Immunogenicity of TBC-M4, a MVA HIV Vaccine Alone or in a Prime-Boost Regimen With ADVAX DNA HIV Vaccine

> **NCT00902824** · PHASE1 · COMPLETED · sponsor: **International AIDS Vaccine Initiative** · enrollment: 32 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** ADVAX
- **BIOLOGICAL:** TBC-M4
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00902824
- **Lead sponsor:** International AIDS Vaccine Initiative
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2010-04
- **Final completion:** 2010-04
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2013-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00902824

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00902824, "Safety and Immunogenicity of TBC-M4, a MVA HIV Vaccine Alone or in a Prime-Boost Regimen With ADVAX DNA HIV Vaccine". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00902824. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*